Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.

NCT05745311 is registered in ClinicalTrials.gov with Kunming Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05745311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05745311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.
Lead sponsor
Kunming Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2023
Completion date
July 30, 2024
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke